by Waylon Wright | Apr 15, 2022
The use of digital therapeutics (DTx) is on the rise. Fueled by shifting models of care as a result of the coronavirus pandemic, the DTx market is expected to reach $10.62 billion by 2025. While DTx offer unique opportunities within the life science product industry,...
by Waylon Wright | Mar 17, 2022
In recent years, there has been an increase in the number of new drugs and therapies developed for rare diseases or specific patient populations. The FDA’s Center for Drug Evaluation and Research approved 50 new drug therapies in 2021. Of those, 26 were considered...
by Waylon Wright | Feb 16, 2022
Pearl Pathways’ own Director of RA/QA Services Becki Nowatzke was honored to serve on the planning committee for this compelling event featuring an outstanding slate of keynote speakers including Jonathan Blum (Principal Deputy Administrator & COO, U.S....
by Waylon Wright | Feb 11, 2022
This is the third of our “Ask the Expert” blogs, a series featuring the wisdom and seasoned insight of Pearl Pathways Advisors and Consultant Advisors. Pearl Pathways Director of QA/RA Services, Beckinam Nowatzke, was interviewed for this piece. If you have any...
by Waylon Wright | Dec 21, 2021
In a previous post, we discussed several of the terms key to the regulatory approval process for drugs and biologics. In this post, we focus on acronyms, abbreviations, and unique terms that industry insiders use in discussions about the regulation and approval of...